Physician profile
Henry Birchmeier
NPI 1497442271
$1,121.82
in general payments reported to CMS, 2019-2025
21 companies · $862 in 2025
The $862 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $260 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $191.59 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $131.65 | 2024-2025 | Airsupra, Breztri |
| Abbvie INC. | $99.53 | 2024-2025 | |
| Glaxosmithkline, LLC. | $87.58 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $86.82 | 2024-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $80.27 | 2025 | Rexulti |
| Exact Sciences Corporation | $58.55 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $58.38 | 2024-2025 | Gvoke Hypopen |
| Amgen INC. | $55.75 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Pfizer INC. | $49.79 | 2024-2025 | |
| Astellas Pharma US INC | $26.64 | 2025 | Veozah |
| Actelion Pharmaceuticals US, INC. | $25.91 | 2025 | Opsumit |
| Recor Medical INC | $21.36 | 2025 | Paradise Ultrasound Renal Denervation System |
| Ars Pharmaceuticals Operations, INC. | $21.29 | 2025 | Neffy |
| Vertex Pharmaceuticals Incorporated | $21.24 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $20.53 | 2025 | |
| Inspire Medical Systems, INC. | $19.49 | 2025 | Inspire |
| Bioventus LLC | $18.47 | 2025 | Xcell |
| Axsome Therapeutics, INC. | $18.34 | 2024 | Auvelity |
| Viatris Specialty LLC | $15.00 | 2025 | Yupelri |
| Depuy Synthes Sales INC. | $13.64 | 2024 | Monovisc, Orthovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Birchmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.